Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis

Universitätsmedizin Mannheim1 site in 1 country105 target enrollmentMarch 2003

ConditionsSepsis

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Sepsis
Sponsor: Universitätsmedizin Mannheim
Enrollment: 105
Locations: 1
Primary Endpoint: New Prognostic markers for septic patients
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Aims of the study were to find vascular markers of inflammation and endothelial damage during the course of severe sepsis in septic patients and the effects of treatment with anti-inflammatory medication (such as Drotregocin alfa (activated)). Another aim is to find new markers and gene polymorphisms for prognosis and mortality of patients with severe sepsis. The hypothesis is that higher plasma concentrations of certain markers in septic patients are associated with a higher mortality rate.

Detailed Description

During the past years many investigators have focused on the immunological changes in sepsis disease, and great attention has been paid to the development of practicable means of immunomonitoring. Human activated protein C (Drotrecogin alfa (activated)), an important coagulation inhibitor plays a major role in regulating microvascular coagulation, inflammation and immunology. Little is known about prognostic vascular biomarkers during the time course of patients with severe sepsis.

Registry

clinicaltrials.gov

Start Date

March 2003

End Date

December 2011

Last Updated

14 years ago

Study Type

Interventional

Study Design

Single Group